NTRK1 and colorectal carcinoma: The therapeutic use of tyrosine kinase receptors inhibitors (TKIs), like Cetuximab or Panitumumab for CRC and Gefitinib or Erlotinib for NSCLC that target EGFR, requires testing of the molecular effectors downstream to the membrane-bound tyrosine kinases and wild type status for these effectors is expected for response to TKIs therapy.